Clinical trials: Cancer, suspended
Gastric Cancer
Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.
To assess the usefulness of Docetaxel plus S-1 combination chemotherapy based on the antitumor effect and survival period by performing a phase I/II study of this combination in Elderly patients with inoperable or with…
- Trial name
- NCT00209729
- Testing
- Taxotere, TS-1
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
This study is planned to include 80 patients with HRD positive HER2-negative advanced breast cancer to receive fluzoparib alone or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of…
- Trial name
- NCT05656131
- Testing
- Fluzoparib, Fluzoparib+Camrelizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- wang shusen
Cancer, Opioid Use
Opioid Misuse in Patients With Cancer
The success of opioid treatment in terminally ill cancer patients set the stage for extending the same treatment principles to the treatment of all chronic pain conditions including chronic non-cancer pain and chronic pain in…
- Conditions
- Cancer, Opioid Use, Opioid Misuse, Pain
- Trial name
- NCT06489769
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Colorectal Cancer, Colorectal Adenoma
Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for CRC Screening
The purpose of this study is to determine the sensitivity and specificity for LifeKit Prevent Colorectal Neoplasia Test for colorectal cancer (CRC) and for adenoma, including advanced adenoma.
- Trial name
- PREVENT (NCT04693546)
- Testing
- LifeKit Prevent Colorectal Neoplasia Test, FIT Test
- Where
- United States
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Metabiomics Corp
Cervical Cancer, Anemia
A Study to Evaluate the Impact of Maintaining Hemoglobin Levels in Anemic Patients With Carcinoma of the Cervix
The purpose of this study is to assess the feasibility, safety and short term effects on health related quality of life, of maintaining hemoglobin from 120 to 130 g/L versus from 100 to 110 g/L, with red cell concentrate (RCC)…
- Trial name
- HOSTT (NCT00921635)
- Testing
- Blood transfusion
- Volunteers
- 2 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Leukemia, Myelodysplastic Syndrome(MDS)
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety and efficacy of fadraciclib (formerly CYC065) administered orally BID.
- Trial name
- NCT05168904
- Testing
- fadraciclib
- Where
- 2 sites in United States
- Volunteers
- 210 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Acute Myeloid Leukemia
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
The goal of this clinical trial is to learn about the efficacy of DASATINIB monotherapy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE.
- Trial name
- VEN-R DASA (NCT06055621)
- Testing
- Dasatinib
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Institut Paoli-Calmettes
High Risk Meningioma, Recurrent Meningioma
68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma
The is phase 1 trial of 68Ga-Dotatate PET/MRI guided radiation dose escalation for high-risk meningiomas (defined as recurrent or subtotal resection of Grade 2, and any Grade 3 meningioma).
- Trial name
- NCT07353229
- Testing
- ⁶⁸Ga-Dotatate PET and MRI Guided Radiation Therapy, Magnetic Resonance Imaging (MRI), 68Ga-Dotatate PET Imaging
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Thomas Jefferson University
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer
This is phase I, open label, multicentre, dose-escalation study where both doses of talazoparib and pidnarulex will be escalated to define the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for the combination.
- Trial name
- REPAIR (NCT05425862)
- Testing
- Pidnarulex, Talazoparib
- Where
- 5 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
NSCLC, Pulmonary Metastases
Study of Outcomes of Radiofrequency Ablation of Lung Tumors
The purpose of this study is to assess short and long term outcomes after radiofrequency ablation (RFA) of pulmonary malignancies in patients who are not candidates for surgical resection.
- Trial name
- NCT00280189
- Testing
- Radiofrequency ablation of pulmonary malignancies, Quality of life assessment, Assessment of pain
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Pittsburgh
Colorectal Carcinoma
A Community-Based Educational Intervention to Improve Colorectal Cancer Screening
This study investigates the facilitators and barriers to colorectal cancer screening in underserved populations with a focus on African American, Latinx, and Asian (Chinese) in the Sidney Kimmel Cancer Center catchment area.
- Trial name
- NCT04392050
- Testing
- Interview, Focus Group, Questionnaire Administration
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Pancreatic Cancer
TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer
This is a Phase I/II study evaluating the intraperitoneal delivery of TROP2 CAR/IL-15 TGFBR2 KO NK cells in combination with oral belzutifan (120 mg daily) for patients with recurrent, locally advanced, unresectable and…
- Trial name
- NCT07377526
- Testing
- TGFBR2 KO CAR27/IL-15 NK cells
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer
Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer
This is a Retrospective, Multicenter, Controlled Study to Evaluate Immunotherapy and Radiotherpay for Brain Lesions as a Potential Treatment for Patients with Brain Metastasis in non-small cell lung cancer
- Trial name
- NCT04835025
- Testing
- PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
Castrate-Resistant Prostate Cancer
LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
This is a single center, single arm Phase I study to establish the safety and efficacy of intravenously administered lentivirally transduced LIGHT-PSMA-specific CAR modified autologous T cells (PSMA-CART cells) in patients with…
- Trial name
- NCT04053062
- Testing
- LIGHT-PSMA-CART cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Bioray Laboratories
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
This phase I trial tests the safety, side effects, and best dose of camu camu when used in combination with nivolumab and ipilimumab in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT06049576
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Prostate Adenocarcinoma, PSA Failure
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
This phase II trial studies how well white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with prostate cancer that has come back (recurrent) or has favorable risk and has not…
- Conditions
- Prostate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate Carcinoma
- Trial name
- NCT04519879
- Testing
- Clinical Observation, Patient Observation, Questionnaire Administration
- Where
- 7 sites in United States
- Volunteers
- 133 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Non-Small-Cell Lung
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages of Non-small Cell Lung Cancer
Randomized Phase III trial of surgery alone or surgery plus preoperative Gemcitabine-Cisplatin in clinical early stages of non-small cell lung cancer
- Trial name
- NCT00540280
- Testing
- Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Hepatocellular Carcinoma
Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).
To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group' in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in China.
- Trial name
- HCC DC CTL (NCT02026362)
- Testing
- MASCT:Multiple Antigens Specific Cellular Therapy, The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- HRYZ Biotech Co.
Multiple Myeloma
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for…
- Trial name
- NCT06179888
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 74 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Cancer, Head and Neck Cancer
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects.
- Conditions
- Gastrointestinal Cancer, Head and Neck Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation
- Trial name
- NCT04541381
- Testing
- Availability of clinical decision support based on pharmacogenomic results.
- Where
- United States
- Volunteers
- 860 people
- Sponsor
- University of Chicago